The most consequential Phase III design decision isn't sample size or endpoints.
It's superiority vs non-inferiority — and the non-inferiority margin.
Get it wrong before enrollment begins and there is no recovery.
#PhaseIII #ClinicalTrials #DrugDevelopment #CRO